MedPath

VIATRIS PHARMA LIMITED

🇭🇰Hong Kong, China
Ownership
-
Established
2020-03-04
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

313

CIMA_AEMPS:283
EMA:30

Drug Approvals

Nintedanib Viatris

Authorization Status
Authorised
Approval Date
Aug 22, 2025
EMA

Emtricitabine / Tenofovir alafenamide Viatris

Authorization Status
Authorised
Approval Date
Jul 18, 2025
EMA

Eltrombopag Viatris

Authorization Status
Authorised
Approval Date
Dec 12, 2024
EMA

Enzalutamide Viatris

Authorization Status
Authorised
Approval Date
Aug 22, 2024
EMA

Enzalutamide Viatris

Authorization Status
Authorised
Approval Date
Aug 22, 2024
EMA

Enzalutamide Viatris

Authorization Status
Authorised
Approval Date
Aug 22, 2024
EMA

Pomalidomide Viatris

Authorization Status
Authorised
Approval Date
Feb 16, 2024
EMA

Dapagliflozin Viatris

Authorization Status
Authorised
Approval Date
Mar 24, 2023
EMA

Pirfenidone Viatris

Authorization Status
Authorised
Approval Date
Jan 10, 2023
EMA

Teriflunomide Mylan

Authorization Status
Authorised
Approval Date
Nov 9, 2022
EMA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.